

International Conference on

Euro Oncology, Breast Cancer & Biomarkers

October 18-19, 2018 | Amsterdam, Netherlands

Selective and immunomodulation properties of the anticancer proton preparation on basis of greater celandine alkaloids NSC 631570



Wassil Nowicky

*Ukrainian Anti-Cancer Institute,
Austria*

One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time, drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC 631570, a property to selectively interact with it without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this, it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. Potent selective antitumor effect of NSC 631570 was repeatedly proven by the results of clinical trials. Until now, this preparation has been tested on over 100 cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at the National Cancer Institute, USA) have shown that the NSC 631570 killed only cancer cells without having damaged the normal cells, which confirmed its selective effect.

Biography

Wassil Nowicky - Dipl. Ing., Dr. techn., DDDR. h. c., Director of "Nowicky Pharma" and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radio technical faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to "Diplomingenieur" in 1960 which title was nostrificated in Austria in 1975. He became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids "NSC-631570". He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Thus, he is invited as an honorable speaker to take part in many scientific international congresses and conferences in USA, Australia, Japan, UAE, Europe. Author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Yanka Kupala State University of Grodno, doctor "honoris causa" of the Open International University on Complex Medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmacists of America, the award of Austrian Society of sanitary, hygiene and public health services and others.

dr.nowicky@yahoo.de

Notes: